Triamcinolone-Associated Crystalline Maculopathy

Archives of Ophthalmology

Volumn 128, Issue 6, 2010, Pages 685-690

  Sarraf, David ^a,b,c   Vyas, Neil ^c   Jain, Atul ^c,d   Bui, Alex ^a   Kertes, Peter J ^e   Bailey Freund, K ^f   Chan, Clement ^g,h  

^a KAISER PERMANENTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c JULES STEIN EYE INSTITUTE   (United States)

^d San Diego Orthopaedic Associates   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

^f NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Southern California Desert Retina Consultants   (United States)

^h LOMA LINDA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRIAMCINOLONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DIABETES MELLITUS; EYE EXAMINATION; EYE FUNDUS; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; MALE; OPTICAL COHERENCE TOMOGRAPHY; OPTICAL TOMOGRAPHY; PHOTOGRAPHY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RETINA EXAMINATION; RETINA MACULA CYSTOID EDEMA; RETINA MACULA EDEMA; RETINA MACULA LUTEA; RETINA MACULOPATHY; VEIN OCCLUSION; VISUAL IMPAIRMENT; VITRECTOMY;

AGED; FEMALE; FLUORESCEIN ANGIOGRAPHY; GLUCOCORTICOIDS; HUMANS; INJECTIONS; MACULA LUTEA; MACULAR EDEMA; MALE; MIDDLE AGED; RETINAL DISEASES; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TRIAMCINOLONE ACETONIDE; VISUAL ACUITY; VITREOUS BODY;

EID: 77953624794     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2010.109     Document Type: Article

References (21)

1. Drenser K, Sarraf D, Jain A, Small KW. Crystalline retinopathies. Surv Ophthalmol. 2006;51(6):535-549.
2. Sarraf D, Ceron O, Rasheed K, Drenser KA, Casey R. West African crystalline maculopathy. Arch Ophthalmol. 2003;121(3):338-342.
3. Bourla DH, Sarraf D, Schwartz SD. Peripheral retinopathy and maculopathy in high-dose tamoxifen therapy. Am J Ophthalmol. 2007;144(1):126-128. (Pubitemid 46963190)
4. Scholes GN, O'Brien WJ, Abrams GW, Kubicek MF. Clearance of triamcinolone from vitreous. Arch Ophthalmol. 1985;103(10):1567-1569.
5. Munir WM, Pulido JS, Sharma MC, Buerk BM. Intravitreal triamcinolone for treatment of complicated proliferative diabetic retinopathy and proliferative vitreoretinopathy. Can J Ophthalmol. 2005;40(5):598-604. (Pubitemid 41564963)
6. Jaissle GB, Szurman P, Völker M, Bartz-Schmidt KU. Epiretinal deposit of triamcinolone acetonide at the posterior pole after intravitreal injection. Ophthalmic Surg Lasers Imaging. 2007;38(3):238-241. (Pubitemid 46953792)
7. Kube T, Sutter M, Trittler R, Feltgen N, Hansen LL, Agostini HT. Carboxymethylcellulose as a new carrier substance for intravitreal injection of reproducible amounts of triamcinolone. Graefes Arch Clin Exp Ophthalmol. 2006;244(11):1385-1390. (Pubitemid 44741247)
8. Bearelly S, Cooney MJ, Stinnett S, Fekrat S. Intravitreal triamcinolone for cystoid macular edema related to branch retinal vein occlusion. Ann Ophthalmol (Skokie). 2006;38(4):317-320.
9. Sutter FK, Kurz-Levin MM, Fleischhauer J, Bösch MM, Barthelmes D, Helbig H. Macular atrophy after combined intravitreal triamcinolone acetonide (IVTA) and photodynamic therapy (PDT) for retinal angiomatous proliferation (RAP). Klin Monbl Augenheilkd. 2006;223(5):376-378.
10. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology. 2008;115(9):1447-1449, e1-e10.
11. Freund KB, Laud K, Eandi CM, Spaide RF. Silicone oil droplets following intravitreal injection. Retina. 2006;26(6):701-703. (Pubitemid 44620379)
12. Jonas JB. Intravitreal triamcinolone acetonide: a change in a paradigm. Ophthalmic Res. 2006;38(4):218-245. (Pubitemid 44213982)
13. Szurman P, Kaczmarek R, Jaissle GB, et al. Influence of different purification techniques on triamcinolone yield and particle size spectrum. Graefes Arch Clin Exp Ophthalmol. 2007;245(5):689-696.
14. Cauchi PA, Sarros M, Atta HR. Deposition of triamcinolone crystals on the posterior lens capsule following prone posturing post-vitrectomy. Acta Ophthalmol Scand. 2006;84(6):828.
15. Szurman P, Sierra A, Kaczmarek R, et al. Different biocompatibility of crystalline triamcinolone deposits on retinal cells in vitro and in vivo. Exp Eye Res. 2007; 85(1):44-53. (Pubitemid 47017266)
16. Szurman P, Kaczmarek R, Spitzer MS, et al. Differential toxic effect of dissolved triamcinolone and its crystalline deposits on cultured human retinal pigment epithelium (ARPE19) cells. Exp Eye Res. 2006;83(3):584-592. (Pubitemid 43902780)
17. Lüke M, Januschowski K, Beutel J, et al. The effects of triamcinolone crystals on retinal function in a model of isolated perfused vertebrate retina. Exp Eye Res. 2008;87(1):22-29.
18. Jaffe GJ, Martin D, Callanan D, Pearson PA, Levy B, Comstock T; Fluocinolone Acetonide Uveitis Study Group. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology. 2006;113(6):1020-1027.
19. Kuno N, Fujii S. Biodegradable intraocular therapies for retinal disorders: progress to date. Drugs Aging. 2010;27(2):117-134.
20. Fialho SL, Rêgo MB, Siqueira RC, et al. Safety and pharmacokinetics of an intravitreal biodegradable implant of dexamethasone acetate in rabbit eyes. Curr Eye Res. 2006;31(6):525-534.
21. Kane FE, Burdan J, Cutino A, Green KE. Iluvien: a new sustained delivery technology for posterior eye disease. Expert Opin Drug Deliv. 2008;5(9):1039-1046.